314 related articles for article (PubMed ID: 25402383)
1. Graves' disease after treatment with alemtuzumab for multiple sclerosis.
Tsourdi E; Gruber M; Rauner M; Blankenburg J; Ziemssen T; Hofbauer LC
Hormones (Athens); 2015; 14(1):148-53. PubMed ID: 25402383
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
Daniels GH; Vladic A; Brinar V; Zavalishin I; Valente W; Oyuela P; Palmer J; Margolin DH; Hollenstein J
J Clin Endocrinol Metab; 2014 Jan; 99(1):80-9. PubMed ID: 24170099
[TBL] [Abstract][Full Text] [Related]
3. Onset of Marine-Lenhart syndrome and Graves' ophthalmopathy in a female patient treated with alemtuzumab for multiple sclerosis.
Le Moli R; Russo M; Malandrino P; Vella V; Belfiore A; Frasca F
Hormones (Athens); 2021 Mar; 20(1):161-165. PubMed ID: 32500462
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review.
Aranha AA; Amer S; Reda ES; Broadley SA; Davoren PM
Endocr Pract; 2013; 19(5):821-8. PubMed ID: 23757618
[TBL] [Abstract][Full Text] [Related]
5. Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease.
Trinh T; Haridas AS; Sullivan TJ
Ophthalmic Plast Reconstr Surg; 2016; 32(6):e128-e129. PubMed ID: 25794019
[TBL] [Abstract][Full Text] [Related]
6. Graves' disease induced by Alemtuzumab in relapsing-remitting multiple sclerosis patients: an observational study in a reference center.
Rodríguez de Vera Gómez P; García-González JJ; Ravé-García R; López Ruiz R; Torres-Cuadro A; Eichau-Madueño S; García-García C; Martín-Hernández T
J Endocrinol Invest; 2022 Oct; 45(10):1977-1990. PubMed ID: 35718853
[TBL] [Abstract][Full Text] [Related]
7. Graves' disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis.
Duarte DB; Silva AMD; Freitas C; Cardoso H
Endocr Regul; 2021 Sep; 55(3):169-173. PubMed ID: 34523298
[No Abstract] [Full Text] [Related]
8. Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.
Alamo A; Condorelli RA; La Vignera S; Calogero AE
Int J Immunopathol Pharmacol; 2019; 33():2058738419843690. PubMed ID: 30968726
[TBL] [Abstract][Full Text] [Related]
9. Management of Graves' hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy.
Laurberg P; Bournaud C; Karmisholt J; Orgiazzi J
Eur J Endocrinol; 2009 Jan; 160(1):1-8. PubMed ID: 18849306
[TBL] [Abstract][Full Text] [Related]
10. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series.
Roos JCP; Moran C; Chatterjee VK; Jones J; Coles A; Murthy R
Eye (Lond); 2019 Feb; 33(2):223-229. PubMed ID: 30498266
[TBL] [Abstract][Full Text] [Related]
11. Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study.
Kazakou P; Tzanetakos D; Vakrakou AG; Tzartos JS; Evangelopoulos ΜE; Anagnostouli M; Stathopoulos P; Kassi GN; Stefanis L; Kilidireas C; Zapanti E
Clin Exp Med; 2023 Oct; 23(6):2885-2894. PubMed ID: 36641771
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcome of Graves' disease in Thai children.
Somnuke PH; Pusuwan P; Likitmaskul S; Santiprabhob J; Sawathiparnich P
J Med Assoc Thai; 2007 Sep; 90(9):1815-20. PubMed ID: 17957924
[TBL] [Abstract][Full Text] [Related]
13. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, Risk Factors, and Clinical and Biochemical Characteristics of Alemtuzumab-Induced Graves Disease.
Ueland GÅ; Ueland HO; Stokland AM; Bhan A; Schønberg A; Sollid ST; Morgas DE; Holmøy T; Lima K; Methlie P; Løvås K; Torkildsen Ø; Husebye ES
J Clin Endocrinol Metab; 2024 Jan; 109(2):344-350. PubMed ID: 37708353
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response.
Rotondi M; Molteni M; Leporati P; Capelli V; Marinò M; Chiovato L
Front Endocrinol (Lausanne); 2017; 8():254. PubMed ID: 29033895
[TBL] [Abstract][Full Text] [Related]
16. [Alemtuzumab-induced Graves' disease].
Sheremeta MS; Korchagina MO; Guseinova RM; Schmidt TE; Nizhegorodova KS; Sviridenko NY; Melnichenko GA
Probl Endokrinol (Mosk); 2023 Jun; 69(3):51-57. PubMed ID: 37448247
[TBL] [Abstract][Full Text] [Related]
17. Management of recurrent hyperthyroidism in patients with Graves' disease treated by subtotal thyroidectomy.
Sugino K; Mimura T; Ozaki O; Iwasaki H; Wada N; Matsumoto A; Ito K
J Endocrinol Invest; 1995 Jun; 18(6):415-9. PubMed ID: 7594234
[TBL] [Abstract][Full Text] [Related]
18. Post-alemtuzumab Graves' disease remitting after switch to ocrelizumab.
Popescu V; Beirinckx A; Decallonne B
Acta Neurol Belg; 2022 Aug; 122(4):1117-1120. PubMed ID: 35589913
[No Abstract] [Full Text] [Related]
19. Alemtuzumab treatment of multiple sclerosis.
Coles AJ
Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214
[TBL] [Abstract][Full Text] [Related]
20. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
